Nutrition 32 (2016) 66-72

Contents lists available at ScienceDirect

# Nutrition

journal homepage: www.nutritionjrnl.com

## Applied nutritional investigation

## Chamomile tea improves glycemic indices and antioxidants status in patients with type 2 diabetes mellitus

Maryam Zemestani M.Sc.<sup>a</sup>, Maryam Rafraf Ph.D.<sup>b,\*</sup>, Mohammad Asghari-Jafarabadi Ph.D.<sup>c</sup>

<sup>a</sup> Students' Research Committee, Faculty of Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran
<sup>b</sup> Nutrition Research Center, Department of Community Nutrition, Faculty of Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran
<sup>c</sup> Tabriz Health Service Management Research Center, Department of Statistics and Epidemiology, Faculty of Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran

## ARTICLE INFO

Article history: Received 2 February 2015 Accepted 21 July 2015

Keywords: Type 2 diabetes mellitus Chamomile Blood glucose Antioxidant status Malondialdehyde

### ABSTRACT

*Objectives:* Oxidative stress is a major factor in the pathogenesis of diabetes complications. The objectives were to investigate the effects of chamomile tea consumption on glycemic control and antioxidant status in subjects with type 2 diabetes mellitus (T2 DM).

*Methods:* This single-blind randomized controlled clinical trial was conducted on 64 subjects with T2 DM (males and females) ages 30 to 60 y. The intervention group (n = 32) consumed chamomile tea (3 g/150 mL hot water) 3 times per day immediately after meals for 8 wk. The control group (n = 32) followed a water regimen for same intervention period. Fasting blood samples, anthropometric measurements, and 3-d, 24-h dietary recalls were collected at the baseline and at the end of the trial. Data were analyzed by independent *t* test, paired *t* test, and analysis of covariance. *Results:* Chamomile tea significantly decreased concentration of glycosylated hemoglobin, serum

insulin levels, homeostatic model assessment for insulin resistance, and serum malondialdehyde, compared with control group (all P < 0.05). Total antioxidant capacity, superoxide dismutase, glutathione peroxidase, and catalase activities were significantly increased by 6.81%, 26.16 %, 36.71 % and 45.06% respectively in chamomile group compared with these variables in control group at the end of the intervention (all P < 0.05).

*Conclusions:* Short term intake of chamomile tea has beneficial effects on glycemic control and antioxidant status in patients with T2 DM. A larger sample population and a longer intervention period may be required to show significant clinical improvements.

© 2016 Elsevier Inc. All rights reserved.

## Introduction

Type 2 diabetes mellitus (T2 DM) is a chronic metabolic disease characterized by hyperglycemia. It has significant effects on health, quality of life, and health care systems. The International Diabetes Federation (IDF) estimates that 439 million people, 7.7% of the world population, will suffer from diabetes by 2030 [1]. Chronic hyperglycemia causes complications of diabetes, such as heart disease, retinopathy, renal disease, and neuropathy [2]. Oxidative stress associated with hyperglycemia is now recognized as the driving force for the development of diabetic complications [3]. Oxidative stress in diabetes is related to activation of the polyol pathway, formation of advanced glycation end products, activation of protein kinase C, and subsequent formation of reactive oxygen species [4–8]. In the absence of a suitable condensation by antioxidant defense system, enhancement of oxidative stress leads to activation of stress-sensitive intracellular signaling pathways and the formation of gene products that cause cellular damage [9–12].

Apart from currently available therapeutic options, like oral hypoglycemic drugs and insulin therapy, which have limitations, many traditional plant medicines have been used in the treatment of diabetes [13]. Plants apparently provide effective remedies, produce only minimal or no side effects in clinical







MR was the main study investigator; MZ worked as an investigator on the study and contributed to the manuscript; MAJ worked on the statistical analysis plans and analyses the results.

<sup>&</sup>lt;sup>c</sup> Corresponding author. Tel.: +984133357580; fax: +984133340634. *E-mail address:* rafrafm@tbzmed.ac.ir (M. Rafraf).

experiment, and are relatively low cost, as compared to oral synthetic hypoglycemic drugs [14].

German chamomile (Matricariachamomilla L.) is an herbaceous plant that is native to Europe and Western Asia [15]. The consumption of chamomile as tea is rated as more than one million cups per day [16]. Current studies have demonstrated its antioxidant, antiparasitic, antiaging, and anticancer properties, supporting its traditional use for treating various human ailments [17–19]. Sesquiterpenic compounds such as  $\alpha$ -bisabolol, bisabolol oxides A and B, chamazulene and farnesene, and phenolic compounds, namely flavonoids including apigenin, quercetin, patuletin and luteolin, and their glucosides, as well as coumarins are considered to be the major bioactive compounds of this plant [20].

Antihyperglycemic and antioxidant activity of chamomile extracts have been demonstrated in experimental studies [21–23]. Cemek et al. indicated that treatment with different doses of chamomile ethanolic extract significantly lowered postprandial hyperglycemia and oxidative stress, and augmented the antioxidant system in streptozotocin (STZ)-induced diabetic rats [21]. In the study by Kholoud and Manal, chamomile aqueous extract effectively decreased blood glucose levels and oxidative stress in STZ-induced diabetic rats [22]. Namjooyan et al. determined that antioxidant activity of chamomile extract reduced the incidence of diabetic embryopathy in the STZ-induced diabetic rat model [23].

Although some experimental studies have reported effects of different extracts of chamomile on glycemic status and oxidative stress in diabetes, its possible effects on metabolic and antioxidant status of patients with diabetes have not been investigated. We hypothesized that chamomile tea consumption would ameliorate glycemic and antioxidant indices in subjects with T2 DM. To test these hypotheses, we initiated a study to evaluate the effects of chamomile tea on glycemic control (serum levels of glucose, glycosylated hemoglobin [HbA1 c], insulin, and homeostasis model assessment-insulin resistance [HOMA-IR]), and antioxidant status (total antioxidant capacity [TAC], activity of superoxide dismutase [SOD] and glutathione peroxidase [GSH-Px], and malondialdehyde [MDA]) in patients with T2 DM.

#### Materials and methods

Sixty-four patients with type 2 diabetes (male & female) ages 30 to 60 y with a body mass index (BMI) lower than 37 kg/m<sup>2</sup> were recruited for this study from the endocrinology clinic, Imam Hossien Hospital in Tehran, Iran from March 2013 to June 2013. Diagnosis of T2 DM was assessed at least six month before our examination. Exclusion criteria included insulin treatment, smoking, alcoholism, consumption of any dietary supplements, green tea, and other herbal infusion in the past 3 mo or during the study. A history of diseases including liver, kidney and cardiovascular diseases, thyroid disorders, gastrointestinal problems, cholesterol-lowering or antihypertension treatment, using corticosteroids, cyclosporine, non-steroidal antiinflammatory or immunosuppressive drugs, warfarin and antiepileptic medications, pregnancy or breast-feeding, following a specific diet and regular exercise (>2 weeks), and allergy to plants of ragweed subject.

The study consisted of a single-blinded randomized, controlled clinical trial with treatment and control groups running in parallel for a period of 8 wk. Ethical Committee of Tabriz University of Medical Sciences approved the study protocol, and was registered on the Iranian Registry of Clinical Trials website (http://www.irct.ir, identifier: IRCT2013012712299 N1). The study was conducted in accordance with the guidelines of the Declaration of Helsinki principles. All subjects gave written informed consent before clinical trial enrolment.

The sample size was determined based on the primary information obtained from the study by Kato et al. for blood glucose [24]. Considering 95% confidence interval and 80% power, and a change of blood glucose in 8 wk as primary outcome of the study, the sample size was computed to be 23 per group. This number was increased to 32 per group to accommodate the anticipated dropout rate. The participants were randomly allocated in two groups using a block

randomization procedure (of size 4) with matched subjects in each block based on sex, age, and body mass index (BMI). The random sequence was generated using random allocation software by the statistician for the study. The endocrinologist randomly assigned participants to an intervention or control group. Whereas patients and the endocrinologist allocated to the intervention group were aware of the allocated group, outcome assessors and the statistician were blinded to the allocation.

A general questionnaire was completed for each subject. Body weight was measured using a scale (Seca, Hamburg, Germany), without shoes and wearing light clothing. Height was measured using a mounted tape without shoes. BMI was calculated as the weight in kilogram divided by the height in meters squared. Information about daily energy and macronutrient intakes were obtained by 24-h recall method for 3 d, including 2 d during the week and 1 during the weekew. A three day average for energy and macronutrient intakes of all subjects were analyzed by Nutritionist 4 software (First Databank Inc., San Bruno, CA).

Chamomile was obtained as homogenous chamomile tea bags (finished product) from the Iranian Institute of medicinal plants, Karaj Iran. The tea bag, containing approximately 3 g of chamomile tea, was manufactured on March 2013. These tea bags are a commercially available product. The intervention group (n = 32) consumed one cup of chamomile tea infusate (1 chamomile tea bag infused for 10 min in 150 mL hot water without milk or sugar) three times a day immediately after meals (breakfast, lunch, and dinner) for 8 wk [24,25]. The control group (n = 32) consumed an equivalent volume of warm water during the 8-wk period (Fig. 1). Subjects were asked to keep a record of all beverages consumed during the clinical trial and maintain their usual dietary intake and physical activity and to avoid any changes in medication, if possible. The compliance of the volunteers for the study protocol was monitored with telephone interviews once a week and counting returned tea bags in person every 2 wk.

#### Blood sampling and biochemical assays

Venous blood samples (5 mL) from each subject were collected between 07:00 to 09:00 h after an overnight fast at the beginning of trial. Two mL of whole blood were collected into tube contained ethylene-diamine-tetra acetic acid to measure the blood levels of HbA1 c. The serum samples were separated from whole blood by centrifugation at 3500 rpm for 10 min (Avanti J-25, Beckman, Brea, CA, USA). The serum and whole blood samples were frozen immediately at  $-70^{\circ}$ C.

Serum glucose was measured using the standard enzymatic methods with commercially available Pars Azmun kit (Karaj, Iran). HbA1 c was measured in the whole blood by cation exchange chromatography with a Nycocard HbA1C kit (Oslo, Norway). Serum insulin level was measured by ELISA method using Monobind kit (Monobind Inc, Lake Forest, CA, USA) and insulin resistance was determined by HOMA index with formula: HOMA-IR = fasting insulin ( $\mu$ U/ mL)  $\times$  fasting glucose (mg/dL)/405 [26]. Serum total cholesterol, triacylglycerol, and high-density lipoprotein cholesterol were measured using the standard enzymatic methods by Pars Azmun kits (Pars Azmun Co., Kirai, Iran), Low-density lipoprotein cholesterol concentration was determined by the Friedewald formula [27]. Measurement of TAC in serum and SOD and GSH-Px in whole blood was performed by using the colorimetric method with commercial kits (TAC. RAN-DOX kits; SOD, RANSOD kits; and GSH-Px, RAN-SEL kits; UK) [28-30]. The serum MDA level was estimated by using a reaction with thiobarbituric acid as a thiobarbituric acid reactive substance to produce a pink colored complex. Next, its fluorescence intensity was measured at 547 nm with excitation at 525 nm by a spectrofluorimeter (model SFM 25 A; Kontron, Milan, Italy) [31]. Catalase (CAT) activity was measured by using the method described by Aebi [32].

All anthropometric, dietary intakes, blood sampling, and biochemical measurements were assessed again at the end of intervention period in both groups.

#### Statistical analyses

Data were analyzed using SPSS version 16 (SPSS Inc., Chicago, IL, USA) and the results are expressed as means  $\pm$  SD. The normal distribution of variables was tested and confirmed by Kolmogorov-Smirnov test. The baseline measurements and dietary intakes of subjects in two groups were compared using independent samples *t* test and chi-square test for quantitative and qualitative variables respectively. Analysis of covariance (ANCOVA) was used to identify any differences between the two groups at the end of study, adjusting for baseline values and covariates. The changes in anthropometric measurements, energy and nutrient intakes, serum levels of glucose, HbA1 c, insulin, HOMA-IR, TAC, SOD, GSH-Px, CAT, and MDA levels between the beginning and end of the study were compared by paired samples *t* test. The percentage of changes in variables after intervention was determined with the formula: [(after values-before values)/ before values] × 100. Results with *P* < 0.05 were considered as statistically significant.




Fig. 1. Flow diagram showing trial profile and study design.

## Results

All of the patients (32 patients in chamomile tea group and 32 patients in placebo group) completed the study (Fig. 1). Compliance was more than 97% of the tea bags in a prescribed manner being consumed during the study period. Participants did not report any adverse effects or symptoms with the chamomile tea consumption during the study.

Anthropometric characteristics and dietary intakes of participants at the beginning and end of the study are shown in Table 1. There were no significant differences between or within groups in weight and BMI at the beginning of the study and after 8 wk of intervention. No significant differences in energy and other dietary intakes were observed between two groups at baseline. Total energy and nutrient intakes also did not change significantly in any of the groups during the study.

Figure 2 (A-D) illustrates changes in serum levels of glucose, HbA1 c, insulin, and HOMA-IR of chamomile tea group and control group during 8-wk period of study. Levels of HbA1 c were not different between two groups at baseline. Significant differences were seen between the two groups in serum levels of glucose, insulin and HOMA-IR at baseline. As shown in Figure 2 (B-D), significant differences were seen between two studied groups in HbA1 c, HOMA-IR, and serum insulin levels at the end of the study adjusted for baseline values, duration of diabetes, intake of oral hypoglycemic agents, and changes of weight and calorie during the study (P < 0.05). Serum glucose levels were in the range of 102 to 332 and 90 to 368 mg/dL in the chamomile tea group, and 111 to 260 and 122 to 238 mg/dL in control group, before and after study, respectively. Changes in serum glucose levels (P = 0.08) was not significant (Fig. 2A). Serum levels of glucose, insulin, HbA1 c, and HOMA-IR significantly decreased in the intervention group by 11.09%, P = 0.004(versus 5.1%, P = 0.28 increase in control group), 32.59%, P < 0.001 (versus 2.5%, P < 0.001 increase in control group), 5.01%, P < 0.001 (versus 0.78%, P = 0.84 increase in control group) and 39.76%, *P* < 0.001 (versus 7.79%, *P* = 0.06 increase in control group), respectively at the end of the study in comparison to baseline values (data not shown). Results of chamomile tea consumption on lipid profile in our study subjects were published in advanced [27]. Based on the findings, serum levels of triacylglycerol, total cholesterol, and low-density lipoprotein cholesterol significantly decreased in the intervention group by 18.35% (versus 5.87% increase in control group), 9.56% (versus 2.97% increase in control group) and 8.85% (versus 5.68% increase in control group) at the end of the study in comparison to baseline values. Levels of serum high-density lipoprotein cholesterol remained unchanged in both groups at the end of study (data not shown).

TAC, enzymatic antioxidants, and MDA levels of subjects at baseline and after 8 wk intervention are shown in Table 2. Significant differences were seen between the two groups in

### Table 1

General characteristics and dietary intakes of diabetic patients at baseline and after 8 wk of intervention

Variable	Measurement	Chamomile	Control group
	period	tea group	(n = 32)
		(n = 32)	
Age (y)	Baseline	$50.19\pm7.08$	$51.97 \pm 6.42$
Height (cm)	Baseline	$160.00\pm6.50$	$162.12\pm 6.34$
Weight (kg)	Baseline	$\textbf{76.00} \pm \textbf{6.71}$	$\textbf{79.65} \pm \textbf{6.62}$
	After intervention	$74.53 \pm 6.48$	$\textbf{79.87} \pm \textbf{6.80}$
BMI (kg/m <sup>2</sup> )	Baseline	$29.48 \pm 2.79$	$\textbf{30.38} \pm \textbf{2.6}$
	After intervention	$29.12\pm3.61$	$\textbf{30.48} \pm \textbf{2.72}$
Metformin 500 mg,	Baseline	$\textbf{2.47} \pm \textbf{0.77}$	$2.17\pm0.75$
tablets/d			
Glibenclamide 5 mg, tablets/d	Baseline	$1.55\pm0.51$	$1.59\pm0.50$
Energy (kcal/d)	Baseline	$1988.2\pm201.2$	$1958.3 \pm 217.1$
	After intervention	$2011 \pm 221$	$1979.1 \pm 248.00$
Carbohydrate (g/d)	Baseline	$298.20\pm40.90$	$298.8\pm53.6$
	After intervention	$303.24\pm38.22$	$293.01\pm54.78$
Protein (g/d)	Baseline	$74.43 \pm 15.82$	$74.79 \pm 14.11$
	After intervention	$76.32 \pm 13.06$	$80.65 \pm 14.49$
Total Fat (g/d)	Baseline	$57.6 \pm 11.8$	$53.3 \pm 10.4$
	After intervention	$57.51 \pm 15.26$	$55.84 \pm 11.89$
Vitamin C (mg)	Baseline	$130.21 \pm 50.51$	$140.86\pm63.94$
	After intervention	$128.86\pm59.16$	$138.22\pm54.55$
Vitamin E (mg)	Baseline	$11.61\pm7.28$	$11.27\pm7.60$
	After intervention	$10.35\pm6.84$	$11.32\pm7.13$
Zinc (mg)	Baseline	$\textbf{8.88} \pm \textbf{3.54}$	$9.13\pm3.14$
	After intervention	$\textbf{9.11} \pm \textbf{2.21}$	$\textbf{9.76} \pm \textbf{2.19}$

BMI, body mass index

The results are described as means  $\pm$  Standard Deviation (SD)


serum levels of TAC, MDA, and activity of SOD and GSH-Px at baseline. Levels of CAT were not different between two groups at baseline. Results of ANCOVA showed statistically significant differences between two studied groups in serum TAC (P = 0.04), MDA (P < 0.001), and activities of CAT (P < 0.001), GSH-Px (P = 0.01), and SOD (P = 0.001) at the end of the study,

adjusted for baseline values, duration of diabetes and changes of weight and calorie during the study. Consumption of chamomile tea increased levels of TAC by 6.81%, SOD by 26.16%, CAT by 45.06%, GSH-Px by 36.71%, and decreased serum levels of MDA by 33.23% compared with these variables in control group. As shown in Table 2, serum levels of TAC and activities of CAT, GSH-Px, and SOD significantly increased in the chamomile tea group (by 15.18%, 36.52%, 49.52%, and 32.5%) at the end of the study. Significant decrease in serum levels of MDA by 45.8% was obtained in chamomile tea group over the 8 wk in comparison to baseline values.

## Discussion

In folk medicine, chamomile tea has been used for antiinflammation, antioxidant action, irritation, and pain relief [15,33]. To our knowledge, only few studies in animals showed antidiabetic and antioxidative potential effects of alcoholic or aqueous extract of chamomile. Based on our literature review, this trial is the first report about the effects of chamomile tea consumption on glycemic indices and antioxidant status in patients with diabetes.

Our findings indicate that drinking chamomile tea significantly decreased serum level of glucose in the intervention group compared to its baseline values and decreased levels of HbA1 c compared to control group. These results are agreement with findings of previous studies in animals [21,22,24,34,35]. Kato et al. reported that aqueous extracts of chamomile (500 mg/kg/d orally) and its major components reduced blood glucose levels in STZ-induced diabetic rats [24]. Eddouks et al. indicated that administration of aqueous extracts of chamomile (20 mg/kg/d) decreased blood glucose levels after 2 wk in normal and STZ-induced diabetic rats [34]. Kholoud and Manal investigated the effects of water extract of chamomile in STZ-induced diabetic rats, and observed significant decrease in blood



**Fig. 2.** Effects of chamomile tea on (A) fasting blood sugar, (B) glycosylated hemoglobin, (C) homeostasis model assessment-insulin resistance (HOMA-IR), and (D) serum insulin. Data were present as means  $\pm$  SE for 32 diabetic patients in each group. <sup>†</sup>P < 0.05 for within group comparisons (paired sample *t* test); <sup>\*</sup>P < 0.05 for between group comparisons (ANCOVA adjusted for baseline value, intake of oral hypoglycemic agents, and changes of weight and calorie during the study and duration of diabetes).

Table 2

	Biochemical parameters of diabetic patients at baseline and after 8 wk of intervention					
Variable Measurement period		Measurement period	Chamomile tea group $(n = 32)$	$Control\ group\ (n=32)$		
	TAC (mmol/L)	Baseline	$1.23\pm0.23$	$1.59\pm0.57$		
		After intervention	$1.41 \pm 0.36$	$1.32\pm0.26$		
		MDA (95% CI), <i>P</i> -value <sup>†</sup>	0.18 (0.09, 0.27), <0.001	-0.26 (-0.45, -0.08), 0.007		
	SOD (U/mg Hb)	Baseline	$1215.04 \pm 292.57$	$1452.35 \pm 302.4$		
		A Ct	1550 1 202 10	1005 04 + 000 00		

Biochemical parameters of diabetic patie	ents at baseline and after 8 wk of intervention

TAC (mmol/L)	Baseline	$1.23 \pm 0.23$	$1.59 \pm 0.57$	0.358 (0.13, 0.57), 0.002*
	After intervention	$1.41 \pm 0.36$	$1.32\pm0.26$	$-0.17~(-0.35,~0.01),~0.04^{\ddagger}$
	MDA (95% CI), <i>P</i> -value <sup>†</sup>	0.18 (0.09, 0.27), <0.001	-0.26 (-0.45, -0.08), 0.007	
SOD (U/mg Hb)	Baseline	$1215.04 \pm 292.57$	$1452.35 \pm 302.4$	237.3 (88.61, 385.99), 0.002*
	After intervention	$1559 \pm 392.19$	$1235.64 \pm 328.06$	$-388.76~(-600.83,~-176.69),~0/001^{\ddagger}$
	MDA (95% CI), <i>P</i> -value <sup>†</sup>	344.92 (211.24, 478.6), <0.001	-216.7 (-346.95, -86.45), 0.002	
GSH-Px (U/g Hb)	Baseline	$30.12 \pm 8.85$	$37.32 \pm 8.51$	-23.83 (-33.07, -14.59), <0.001*
	After intervention	$41.74 \pm 14.65$	$30.53 \pm 9.99$	$-10.07~(-18.42,-1.72),0.01^{\ddagger}$
	MDA (95% CI), <i>P</i> -value <sup>†</sup>	11.62 (5.82, 17.43), <0.001	-6.78 (-10.89, -2.67), 0.002	
Catalase (U/g Hb)	Baseline	$61.42 \pm 24.5$	$67.45 \pm 23.47$	6.02 (-5.96, 18.01), 0.319*
	After intervention	$76.71 \pm 23.12$	$52.88 \pm 12.17$	$-29.09~(-39.91,~-18.26)$ , $<\!0.001^{\ddagger}$
	MDA (95% CI), <i>P</i> -value <sup>†</sup>	15.28 (5.31, 25.26), 0.004	-14.56 (-22.59, -6.54), 0.001	
MDA (nmol/mL)	Baseline	$4.29 \pm 1.72$	$2.95 \pm 1.66$	$-1.34$ ( $-2.18$ , $-0.49$ ), $0.002^{*}$
	After intervention	$2.27 \pm 1.2$	$3.4\pm1.72$	2.07 (1.29, 2.84), <0.001 <sup>‡</sup>
	MDA (95% CI), P-value <sup>†</sup>	-2.02 ( $-2.46$ , $-1.58$ ), $<0.001$	0.45 (-0.08, 0.98), 0.098	

MDA, malondialdehyde; TAC, total antioxidant status; SOD, superoxide dismutase; GSH-Px, glutathione peroxidase; CI, confidence interval The results are described as means  $\pm$  SD

MD (95% CI), P-value is reported based on the analysis of independent sample t test.

MD (95% CI), P-value is reported based on the analysis of paired sample t test.

<sup>‡</sup> MD (95% CI), *P*-value is reported based on the analysis of covariance.

glucose after 21 d with 100 mg/kg/d extract administered orally [22]. Other studies also showed significant effects of ethanolic extract of chamomile by different dosages and period in diabetic rats [21,35]. Also, we previously reported that chamomile tea improved lipid profile indexes [27].

It was suggested that antihyperglycemic activity of chamomile might be due to stimulation of peripheral glucose, especially in muscle and adipose tissue, and/or inhibition of key enzymes involved in the gluconeogenesis and glycogenolysis pathways. Modulation of PPARs and other factors by chamomile extract might be another related mechanism(s). In addition, esculetin and quercetin, two major constituents of chamomile, inhibit intestinal α-glucosidase activities and decrease blood glucose in STZ-diabetic rats [24]. Luteolin and quercetin were shown to inhibit hepatic glycogen phosphorylase and increase liver glycogen content [24]. Chlorogenic acid, a phenolic acid present in chamomile flowers, may slow down carbohydrate absorption by inhibiting intestinal glucose transport [36].

Exposure to hyperglycemia for a long time induces oxidative stress and decreases capacities of the endogenous antioxidant defense system, which leads to production of several reducing sugars [37]. Reactive oxygen species react with lipids, which causes peroxidative changes that result in elevated lipid peroxidation products such as MDA [38]. TAC is an indicator of the overall protective effect of antioxidants in body fluids, on cell membranes, and other components of cells against oxidative injury [39]. SOD, GSH-Px, and CAT are nonenzymatic antioxidants which play a role in the repair of free radicals exposed to biological damage. SOD catalyzes the conversion of superoxide radical to hydrogen peroxide and molecular oxygen. CAT promotes the reduction of hydrogen peroxides and protects the tissues against reactive hydroxyl radicals [21].

According to our results, chamomile tea consumption caused a considerable increase in TAC level, SOD, GSH-Px, and CAT activity and decreased MDA levels. Such valuable results might be due to chamomile's antihyperglycemic property, which was demonstrated in the treated group.

Our findings also were comparable with findings of other studies which reported decreased serum MDA and increased

CAT and GSH-Px activity [22], elevated TAC levels [40], reduced serum MDA levels, and increased CAT and SOD activity [21] in diabetic rats after administrations of chamomile aqueous or ethanolic extracts. Moreover several studies demonstrated that aqueous extracts of chamomile had higher activity than the ethanolic ones [15]. Other studies showed moderate antioxidant activity of chamomile methanolic, ethanolic, or aqueous extracts in comparison with a selection of other medicinal plants [18,41–43]. Braga et al. reported that  $\alpha$ -Bisabolol, one of the active components of chamomile [20], improved the antioxidant network and restored the redox balance by antagonizing oxidative stress [44]. In the study by Yoo et al., chamomile enhanced the activity of antioxidative enzymes such as SOD and CAT and cell viability in a dose-dependent manner. In the same study, chamomile provided protective effects against oxidative stress induced by hydrogen peroxide in lung fibroblasts [45].

MDA (95% CI), P-value

It was demonstrated that chamomile has high levels of polyphenolic compounds such as coumarins and flavonoids which are reported to produce free radical scavenger actions. The coumarins, herniarin, umbelliferone, and esculetin make up approximately 0.1% of the total constituents. The major flavonoids components are apigenin, luteolin, and quercetin, which comprise 16.8, 1.9, and 9.9% of total flavonoids [24]. Hence, chamomile is one of the richest sources of dietary antioxidants. Our results confirmed that chamomile tea had antioxidant capability and ameliorated the oxidative stress in studied subjects. It was possible that the increase in TAC and activities of enzymatic antioxidants in our chamomile treated group might be due to their decreased consumption for free radical detoxification or utilization which was approved by following decrease in serum MDA and enhancement in TAC levels. Therefore, the antihyperglycemic and antioxidant effect of chamomile tea may be ascribed for the reduction of oxidative stress.

Besides the mechanisms mentioned above, Kholoud and Manal reported that another possible protective effect of chamomile against oxidative stress, at least in part, might be via restoration of nitric oxide availability [22]. Nevertheless, we did not evaluate this phenomenon in our subjects. Further studies are warranted to evaluate the availability of nitric oxide in patients with diabetes. Collectively, on the basis of our findings, the research hypotheses regarding chamomile tea consumption would ameliorate glycemic and antioxidant indices in subjects with T2 DM were accepted.

It should be noted that in the present study, the subjects were asked to maintain their former diet during the study and data indicated that the subject's diet did not change significantly during the intervention trial. Thus, dietary factors could not be considered as confounding factors in the interpretation of studied biochemical variables. It was also expected that the randomized design could balance eventual bias between the study and control groups. However, our study had some limitations, including its single blind design, short study duration of 8 wk, and discrepancy regarding sex. In addition, effects of chamomile components on metabolic parameters may be dose dependent [21]. The interpretation of the results of our present study may not be applicable for using other amounts of chamomile tea or other intervention periods or for patients under other diabetic medications.

## Conclusion

The present study demonstrates that short term intake of chamomile tea had beneficial effects on glycemic control and antioxidant status in patients with T2 DM. A larger sample population and a longer intervention period may be required to show significant clinical improvements.

## Acknowledgments

We thank The Nutrition Research Center of Tabriz University of Medical Sciences, Tabriz, Iran for the financial support and the patients who participated in the study. We would like to thank all of the investigators, coordinators, and patients who took part in this study. This article was written based on data set of MSc thesis (number 183) registered in Tabriz University of Medical Sciences, Iran.

## References

- Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4–14.
- [2] Nolte MS, Karam JH. Pancreatic hormones and antidiabetic drugs. Basic Clin Pharmacol 2004;9:693–715.
- [3] Kawahito S, Kitahata H, Oshita S. Problems associated with glucose toxicity: Role of hyperglycemia-induced oxidative stress. World J Gastroenterol 2009;15:4137–42.
- [4] Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care 2003;26:1589–96.
- [5] Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010;107:1058–70.
- [6] Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD (P) H oxidase in cultured vascular cells. Diabetes 2000;49:1939–45.
- [7] Lee JL, Suh KS, Choi MC, Chon S, Oh S, Woo JT, et al. Kaempferol protects HIT-15 pancreatic beta-cells from 2-deoxy-D-ribose-induced oxidative damage. Phytother Res 2010;24:419–23.
- [8] Altan N, Sepici-Dinc el A, Koca C. Diabetes mellitus and oxidative stress. Turk J Biochem 2006;31:51–6.
- [9] Nourooz-Zadeh J, Rahimi A, Tajaddini-Sarmadi J, Tritschler H, Rosen P, Halliwell B, et al. Relationships between plasma measures of oxidative stress and metabolic control in NIDDM. Diabetologia 1997;40:647–53.
- [10] Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813–20.
- [11] Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress an stressactivated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 2002;23:599–622.
- [12] Shih C, Wu Y, Lin W. Antihyperglycaemic and antioxidant properties of anoectochilus formosanus in diabetic rats. Clin Exp Pharmacol Physiol 2002;29:684–8.

- [13] Mukherjee P, Maiti K, Mukherjee K, Houghton PJ. Leads from Indian medicinal plants with hypoglycemic potentials. J Ethnopharmacol 2006;106:1–28.
- [14] Gupta S, Mal M, Bhattacharya P. Evaluation of hyperglycemia potential of S. xanthocarpum fruit in normal and streptozotocin induced diabetic rats. Eur Bull Drug Res 2005;13:51–5.
- [15] Mckay DL, Blumberg JB. A review of the bioactive and potential health benefits of chamomile tea (Matricariarecutita L). Phytother Res 2006;20:519–30.
- [16] Maschi O, Dal Cero E, Galli GV, Caruso D, Bosisio E, Dell'Agli M. Inhibiton of human cAMP-phosphodiesterase as a mechanism of spasmolytic effect of Matricariarecutita L. J Agric Food Chem 2008;56:5015–20.
- [17] Babenko NA, Shakhova EG. Effects of chamomilla recutita flavonoids on age-related liver sphingo lipid turnover in rats. Exp Gerontol 2006;41:32–9.
- [18] Lee KG, Shibamoto T. Determination of antioxidant potential of volatile extracts isolated from various herbs and spices. J Agric Food Chem 2002;50:4947–52.
- [19] Srivastava JK, Gupta S. Health promoting benefits of chamomile in the elderly population. Complementary and Alternative Therapies and the Aging Population: An Evidence-Based Approach 2011;135.
- [20] Petronilho S, Maraschin M, Coimbra MA, Rocha SM. In vitro and in vivo studies of natural products: A challenge for their valuation. The case study of chamomile (matricariarecutita L.). Ind Crop Prod 2012;40:1–12.
- [21] Cemek M, Kaga S, Simsek N, Buyukokuroglu ME. KonukM. Antihyperglycemic and antioxidative potential of matricariachamomilla L. in streptozotocin-induced diabetic rats. J Nat Med 2008;62:284–93.
- [22] Kholoud SR, Manal AE. Biochemical evalution of antihyperglycemic and antioxidative effects of matricaria chamomilla leave extract studied in streptozotocin-induced diabetic rats. Int J Res Mang Technol 2012;2:298– 302.
- [23] Namjooyan F, Panahi M, Ahmadpour F, Darvish A, Azemi M, Khodayar M, et al. Antioxidant capacity of matricaria chamomilla L. extract and its effect on neural tube structure in diabetic rat offspring. Planta Med 2011;77.
- [24] Atsushi K, Yuka M, Jo Y, Isao A, Alison AW, Robert JN. Protective effects of dietary chamomile tea on diabetic complications. J Agric Food Chem 2008;56:8206–11.
- [25] Christopher W, Sylvia JW, Morten R, Anja F, Vitam K, Heba A, et al. Antidiabetic effects of chamomile flowers extract in obese mice through transcriptional stimulation of nutrient sensors of the peroxisome proliferator-activated receptor (PPAR) family. PLoS One 2013;8:1–16.
- [26] Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–9.
- [27] Rafraf M, Zemestani M, Asghari-Jafarabadi M. Effectiveness of chamomile tea on glycemic control and serum lipid profile in patients with type 2 diabetes. J Endocrinol Invest 2014;38:163–70.
- [28] Miller NJ, Rice-Evans C, Davies MJ, Gopinathan V, Milner A. A novel method for measuring antioxidant capacity and its application for monitoring the antioxidant status in premature neonates. Clin Sci 1993;84:407–12.
- [29] Winterbourn CC, Hawkins RE, Brian M, Carrel RW. Red cell superoxide dismutase activity. J Lab Clin Med 1975;85:337–50.
- [30] Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967;70:158–69.
- [31] Del Rio D, Pellegrini N, Colombi B, Bianchi M, Serafini M, Torta F, et al. Rapid fluorimetric method to detect total plasma malondialdehyde with mild derivatization conditions. Clin Chem 2003;49:690–2.
- [32] Aebi H. Catalase in vitro. Meth Enzymol 1984;105:121-6.
- [33] Srivastava JK, Gupta S. Antiproliferative and apoptotic effects of chamomile extract in various human cancer cells. J Agric Food Chem 2007;55:9470-8.
- [34] Eddouks M, Lemhadri A, Zeggwagh NA, Michel JB. Potent hypoglycaemic activity of the aqueous extract of Chamaemelum nobile in normal and streptozotocin-induced diabetic rats. Diabetes Res Clin Pract 2005;67:189–95.
- [35] Darvishpadok A, Azemi M, Namjoyan F, Khodayar M, Ahmadpour F, Panahi M. Effect of Matricariachamomilla L. on blood glucose and glycosylated hemoglobin in female fertile diabetic rats. Res Pharm Sci 2012;7:19.
- [36] McCarty MF. Nutraceutical resources for diabetes prevention—an update. Med Hypotheses 2005;64:151–8.
- [37] Robertson RP, Harmon JS. Diabetes, glucose toxicity, and oxidative stress: a case of double jeopardy for the pancreatic islet beta cell. Free Radic Biol Med 2006;41:177–84.
- [38] Rishi P, Mavi SK, Bharrhan S, Shukla G, Tewari R. Protective efficacy of probiotic alone or in conjunction with a prebiotic in Salmonella-induced liver damage. FEMS Microbiol Ecol 2009;69:222–30.
- [39] Koca K, Yurttas Y, Cayci T, Bilgic S, Kaldirim U, Durusu M, et al. The role of preconditioning and N-acetylcysteine on oxidative stress resulting from tourniquet-induced ischemia-reperfusion in arthroscopic knee surgery. J Trauma Acute Care Surg 2011;70:717–23.
- [40] Manal AE. Comparative evaluation of antidiabetic activity of rosmarinus officinalis L. and Chamomile recutita in streptozotocin induced diabetic rats. Agr Biol J N Am 2012;3:247–52.

- [41] Dragland S, Senoo H, Wake K, Holte K, Blomhoff R. Several culinary and medicinal herbs are important sources of dietary antioxidants. J Nutr 2003;133:1286–90.
- [42] Koleckar V, Opletal L, Brojerova E, Rehakova Z, Cervenka F, Kubikova K, et al. Evaluation of natural antioxidants of leuzea carthamoides as a result of a screening study of 88 plant extracts from the European ateraceae and cichoriaceae. J Enzyme Inhib Med Chem 2008;23: 218–24.
- [43] Al-Ismail KM, Aburjai T. Antioxidant activity of water and alcohol extracts of chamomile flowers, anise seeds and dill seeds. J Sci Food Agric 2004;84:173–8.
- [44] Braga PC, Dal Sasso M, Fonti E, Culici M. Antioxidant activity of bisabolol: inhibitory effects on chemiluminescence of human neutrophil bursts and cell free systems. Pharmacology 2009;83:110–5.
- [45] Yoo KM, Lee CH, Lee H, Moon BK, Lee CY. Relative antioxidant and cytoprotective activities of common herbs. Food Chem 2008;106:929–36.